Edition:
United States

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Global Select Market

59.30USD
21 Sep 2018
Change (% chg)

$-0.95 (-1.58%)
Prev Close
$60.25
Open
$60.10
Day's High
$61.70
Day's Low
$57.70
Volume
798,946
Avg. Vol
149,618
52-wk High
$64.15
52-wk Low
$9.60

Latest Key Developments (Source: Significant Developments)

Mirati Therapeutics Announces Progress Of Lead Programs
Tuesday, 24 Apr 2018 04:15pm EDT 

April 24 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS ANNOUNCES PROGRESS OF LEAD PROGRAMS AND PROVIDES UPDATED POSITIVE CLINICAL TRIAL RESULTS FOR IMMUNO-ONCOLOGY COMBINATION TRIALS.MIRATI THERAPEUTICS INC - MRTX849 ON TRACK FOR AN INVESTIGATIONAL NEW DRUG SUBMISSION IN Q4 OF 2018.MIRATI THERAPEUTICS - SITRAVATINIB BEING EVALUATED IN PHASE 2 STUDY IN COMBINATION WITH NIVOLUMAB HAS BEEN WELL-TOLERATED.  Full Article

Mirati Therapeutics Q4 Loss Per Share $0.67
Thursday, 8 Mar 2018 04:30pm EST 

March 8 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.67.Q4 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.  Full Article

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 06:00am EST 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Mirati prices public offering of 2 mln shares at $13 per share​
Thursday, 16 Nov 2017 08:45am EST 

Nov 16 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics announces pricing of public offering of common stock.Mirati Therapeutics Inc - ‍pricing of underwritten public offering of 2 million shares of its common stock at a price to public of $13.00 per share​.  Full Article

Mirati announces advancement of opportunities with inhibitor programs
Monday, 13 Nov 2017 04:15pm EST 

Nov 13 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs.Mirati Therapeutics - ‍"reprioritizing" development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​.Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​.  Full Article

Mirati Therapeutics reports Q3 loss per share of $0.65
Wednesday, 1 Nov 2017 04:30pm EDT 

Nov 1 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.65.Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S.‍Research and development expenses for Q3 of 2017 were $13.5 million, compared to $16.1 million for same period in 2016​.  Full Article

Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
Thursday, 12 Oct 2017 04:45pm EDT 

Oct 12 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients.  Full Article

Mirati Therapeutics presents positive data from on-going clinical trials of sitravatinib
Thursday, 14 Sep 2017 04:33pm EDT 

Sept 15 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics Inc presents positive preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer.Mirati Therapeutics Inc - in both clinical studies, Sitravatinib alone and in combination with nivolumab was well tolerated with a manageable safety profile.  Full Article

Mirati Therapeutics reports Q2 loss per share $0.74
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.74.Q2 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.Mirati Therapeutics - ‍cash, cash equivalents, and short-term investments were $87.8 million at june 30, 2017, compared to $56.7 million at December 31, 2016​.  Full Article

Mirati Therapeutics Q1 loss per share $0.73
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics - expect currently available cash, cash equivalents and short-term investments sufficient to fund operations into late 2018.Mirati Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.73.Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.  Full Article